COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06BDE
|
|||
| Drug Name |
Remdesivir
|
|||
| Synonyms |
L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | Middle East Respiratory Syndrome (MERS) | Investigative | [2] | Severe acute respiratory syndrome (SARS) | Investigative | [2] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Gilead Sciences, Foster City, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H35N6O8P
|
|||
| Canonical SMILES |
CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
|
|||
| InChI |
1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
|
|||
| InChIKey |
RWWYLEGWBNMMLJ-YSOARWBDSA-N
|
|||
| CAS Number |
CAS 1809249-37-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:145994
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2], [3] |
| The mechanism of remdesivirs against SARS-CoV-2 is through premature termination of viral RNA transcription. | ||||
| MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2] | |
| The mechanism of remdesivir against MERS-CoV (EC50 = 0.07 microM) is through premature termination of viral RNA transcription. | ||||
| SARS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2] | |
| The mechanism of Remdesivir against SARS-CoV (EC50 = 0.07 microM) is through premature termination of viral RNA transcription. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | ClinicalTrials.gov (NCT04315948) Trial of Treatments for COVID-19 in Hospitalized Adults | |||
| 2 | Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. | |||
| 3 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.